David Akirtava, PhD

With Open Payments it is possible for Pfizer to better understand its own investigator usage pattern and how that pattern may differ from the practices of other pharmaceutical companies.

With Open Payments US investigator names and experience will become public knowledge.

More recent ClinicalTrials.gov data indicate that the United States remains the central location for clinical trial activity.

With the pharmaceutical industry looking for new investigators, a non-commercial clinical trial has become an under appreciated source.

A data analysis focusing on where US investigators conduct clinical trials.